Posted by Michael Wonder on 21 Nov 2021
Moderna files for authorisation of its COVID-19 vaccine with Health Canada to include children ages 6-11 years
17 November 2021 - Submission based on Phase 2/3 study of SPIKEVAX in children ages 6 to 11.
Moderna today announced that it has submitted for authorization with Health Canada for the evaluation of a 50 µg two dose series of Spikevax (elasomeran mRNA vaccine) in children ages 6 to 11 years.
